Uncommon Cents Investing LLC Has $748,000 Stock Position in Fresenius Medical Care AG (NYSE:FMS)

Uncommon Cents Investing LLC boosted its stake in Fresenius Medical Care AG (NYSE:FMS) by 8.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,810 shares of the company’s stock after acquiring an additional 2,890 shares during the period. Uncommon Cents Investing LLC’s holdings in Fresenius Medical Care were worth $748,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Bruce G. Allen Investments LLC bought a new stake in shares of Fresenius Medical Care during the 4th quarter valued at about $31,000. Hartford Financial Management Inc. lifted its stake in Fresenius Medical Care by 98.8% in the fourth quarter. Hartford Financial Management Inc. now owns 1,688 shares of the company’s stock valued at $35,000 after buying an additional 839 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Fresenius Medical Care by 349.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,314 shares of the company’s stock worth $48,000 after buying an additional 1,799 shares in the last quarter. GAMMA Investing LLC acquired a new stake in shares of Fresenius Medical Care during the 4th quarter worth approximately $67,000. Finally, Assetmark Inc. grew its position in shares of Fresenius Medical Care by 169.9% during the 4th quarter. Assetmark Inc. now owns 4,178 shares of the company’s stock worth $87,000 after buying an additional 2,630 shares during the period. Institutional investors and hedge funds own 8.25% of the company’s stock.

Wall Street Analyst Weigh In

FMS has been the topic of a number of research reports. Truist Financial boosted their target price on shares of Fresenius Medical Care from $21.00 to $24.00 and gave the company a “hold” rating in a research report on Wednesday, May 15th. StockNews.com assumed coverage on shares of Fresenius Medical Care in a report on Wednesday. They set a “strong-buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Fresenius Medical Care has a consensus rating of “Hold” and a consensus price target of $32.25.

Fresenius Medical Care Stock Up 0.4 %

Shares of FMS traded up $0.07 during trading hours on Thursday, reaching $19.23. The stock had a trading volume of 104,869 shares, compared to its average volume of 357,919. The company has a market capitalization of $11.28 billion, a price-to-earnings ratio of 21.61, a P/E/G ratio of 1.02 and a beta of 0.90. The firm has a 50-day simple moving average of $20.72 and a 200 day simple moving average of $20.15. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 0.46. Fresenius Medical Care AG has a 12 month low of $16.37 and a 12 month high of $27.72.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.10. The firm had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.15 billion. Fresenius Medical Care had a net margin of 2.48% and a return on equity of 5.29%. Equities research analysts predict that Fresenius Medical Care AG will post 1.5 earnings per share for the current fiscal year.

Fresenius Medical Care Cuts Dividend

The business also recently disclosed an annual dividend, which was paid on Monday, June 3rd. Shareholders of record on Monday, May 20th were issued a dividend of $0.437 per share. This represents a yield of 2.35%. The ex-dividend date was Friday, May 17th. Fresenius Medical Care’s dividend payout ratio is currently 49.44%.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.